Vol. 5 No. 3 (2025)
Reimbursement Reviews

Danicopan (Voydeya)

decorative image of the issue cover

Published March 19, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses danicopan (Voydeya), 50 mg and 100 mg film-coated tablets, oral administration.
  • Indication: As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).